The Sage Group

Western Europe – Prevalence and Incidence of Peripheral Artery Disease and Critical Limb Ischemia 2017

Research on the epidemiology of peripheral artery disease (PAD) and critical limb ischemia (CLI) remains sparse. Since the 2010 publication of Critical Limb Ischemia Volume II Western Europe Epidemiology, almost no country-specific new epidemiological studies have been published. However, a considerable amount of data has been published on the growing prevalence of diabetes.

Over the last seven years, diabetes has increased significantly in Western Europe. This is particularly true in the elderly, the population at highest risk for developing PAD and CLI. According to our estimates, the epidemic of diabetes in the elderly and middle-aged population has caused substantial increases in the prevalence of PAD and CLI in most of the Western European countries

The new 2017 publication contains a comprehensive analysis of the most recently reported prevalence of diabetes in each of the 15 major Western European markets. The 15 countries include: Germany, Italy, Spain, the U.K., France, Greece, the Netherlands, Austria, Switzerland, Belgium, Portugal, Sweden, Finland, Denmark and Norway.

Employing the Diabetes Method, the 2015 prevalence of PAD and CLI are estimated for each country, and the prevalence of each is projected for the 2015-2030 period. These revised prevalence estimates are compared with THE SAGE GROUP’S previous estimates published in 2010. THE SAGE GROUP’S estimates are also compared with PAD and CLI estimates based on available country-specific studies.

The Diabetes Method is an age- and glucose-based method to estimate atherosclerotic lower limb disease. Employing U.S. Census Bureau’s International Data Base (IDB), the population is segmented into 3 age groups. Within each of these age groups, the population is divided into two glucose states: Diabetic (diagnosed and undiagnosed) and Nondiabetic (normal glucose and prediabetes). PAD is calculated according to the percentage prevalence in each glucose state. Then the prevalence of CLI is calculated in those with PAD by glucose status.

PAD and CLI incidence estimates are included for 2015-2030.

Prevalence is defined as the number of new and old cases of PAD and CLI. Incidence is defined as the annual number of new cases of these diseases.

Price: $6,200

To purchase: